Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24406209 | 1.00 | KMT2A (0.56) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL28669272 | 0.89 | KMT2A (0.49) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL30886057 | 0.86 | KMT2A (0.60) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL21452895 | 0.86 | KMT2A (0.60) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL27443282 | 0.86 | KMT2A (0.52) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL24784818 | 0.85 | KMT2A (0.46) | KMT2AOPRD1EPHX2MDM4TP53 | |
| SCHEMBL27443201 | 0.85 | KMT2A (0.49) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL28803723 | 0.84 | OPRD1 (0.56) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL31534694 | 0.84 | KMT2A (0.49) | KMT2AOPRD1CASP3EPHX2FABP5 | |
| SCHEMBL30125177 | 0.83 | KMT2A (0.67) | KMT2AOPRD1CASP3EPHX2FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739347-A1 | CONJUGATES OF DRUG UNITS AND TARGETING UNITS AND PRECURSOR COMPOUNDS THEREOF | Solve Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025014830-A1 | CONJUGATES OF DRUG UNITS AND TARGETING UNITS AND PRECURSOR COMPOUNDS THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | NR3C1, SSB, SERPINA6 | KMT2A 2035/4885OPRD1 4271/4885CASP3 4180/4885 |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | PCNA, POLI, VIP | KMT2A 4145/4885OPRD1 3295/4885CASP3 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.